Business Context and Reporting Period
This Form 6-K filing by Ascendis Pharma A/S, dated June 9, 2025, reports on the Week 26 interim analysis results of the ongoing COACH Trial. The trial evaluates the combination treatment of once-weekly investigational TransCon CNP (navepegritide) and once-weekly TransCon hGH (lonapegsomatropin) in children with achondroplasia.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial data and does not contain financial statements or operational financial metrics.
Material Changes and Clinical Results
The filing details significant clinical outcomes from the COACH Trial interim analysis:
- Combination Efficacy: TransCon hGH boosted the treatment benefits of TransCon CNP, resulting in significant growth and proportionality improvements.
- Growth Velocity (Treatment-Naïve Cohort): Mean annualized growth velocity (AGV) was 9.14 cm/year, an increase of 4.23 cm/year from baseline. Mean ACH height Z-score improved by +0.53.
- Growth Velocity (TransCon CNP-Treated Cohort): Mean AGV was 8.25 cm/year, an increase of 3.10 cm/year from baseline. Mean ACH height Z-score improved by +0.44.
- Comparative Performance: Mean AGV with combination treatment exceeded the 97th percentile of average-stature children.
- Safety Profile: Safety and tolerability were consistent with monotherapies; combination treatment was generally well tolerated with generally mild treatment-emergent adverse events (TEAEs).
Guidance, Outlook, and Risks
Outlook and Timeline:
- Week 52 data from the COACH Trial is expected in Q4 2025.
- Ascendis plans to initiate a Phase 3 trial in Q4 2025.
Risks and Contingencies:
- Forward-looking statements regarding trial timelines and Phase 3 initiation are subject to substantial risks and uncertainties.
- Key risks include dependence on third-party manufacturers, unforeseen safety or efficacy results, unforeseen expenses, regulatory delays, patient recruitment speed, and the ability to obtain additional funding.
- International economic, political, and trade factors may impact operations.
Investor Verification Checklist
- Verify the full safety data and long-term tolerability profile beyond the 26-week interim period.
- Confirm the specific criteria and regulatory pathway for the planned Phase 3 trial initiation in Q4 2025.
- Monitor the Week 52 data release in Q4 2025 to assess durability of growth velocity and proportionality improvements.
- Review the company's cash position and funding requirements in the most recent Form 20-F to assess ability to fund Phase 3 development.
- Assess the regulatory status of TransCon CNP monotherapy under FDA priority review and its potential impact on combination therapy approval.